Valuation: TScan Therapeutics, Inc.

Market Cap 60.33M 52.74M 48.65M 44.73M 84.74M 5.8B 86.19M 581M 228M 2.84B 227M 222M 9.78B P/E 2026 *
-1.05x
P/E 2027 * -1x
Enterprise Value -38.54M -33.7M -31.09M -28.57M -54.14M -3.71B -55.07M -371M -146M -1.81B -145M -142M -6.25B EV / Sales 2026 *
-5.1x
EV / Sales 2027 * -1.85x
Free-Float
93.27%
Yield 2026 *
-
Yield 2027 * -
06-22 TScan Therapeutics Presents Initial Data from Cohort C of Ongoing ALLOHA Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation CI
06-22 TScan Therapeutics Reports Positive Data From Trial of Blood Cancer Treatment MT
06-03 Cellares and TScan Therapeutics Inc. Announce Agreement To Evaluate Automated Manufacturing Of TSC-101 CI
05-06 TScan Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
04-02 TScan Therapeutics, Inc. Announces Executive Changes, Effective April 10, 2026 CI
03-04 TScan Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 CI
02-26 TScan Therapeutics completes enrollment in cohort C of Phase 1 Alloha(TM) trial RE
02-26 TScan Therapeutics, Inc. Completes Enrollment in Cohort C of Phase 1 AlloHA Trial and Announces FDA Clearance of Investigational New Drug Applications for Heme Candidates TSC-102-A03 CI
12-19 TScan Therapeutics, Inc.(NasdaqGM:TCRX) dropped from NASDAQ Biotechnology Index CI
12-07 TScan Therapeutics Announces Positive Updated Data from the AlloHA Phase 1 Heme Trial at the 67th American Society of Hematology Annual Meeting and Exposition CI
11-14 Morgan Stanley Downgrades TScan Therapeutics to Equalweight From Overweight MT
11-12 TScan Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 CI
11-12 TScan Therapeutics Q3 revenue jumps RE
1 day-0.74%
1 week-26.74%
Current month-5.82%
1 month-2.87%
3 months-13.73%
6 months-19.03%
Current year-7.69%
1 week 0.9
Extreme 0.905
1.1
1 month 0.83
Extreme 0.8251
1.28
Current year 0.83
Extreme 0.8251
1.47
1 year 0.83
Extreme 0.8251
2.57
3 years 0.83
Extreme 0.8251
9.69
5 years 0.83
Extreme 0.8251
14.71
10 years 0.83
Extreme 0.8251
14.71
Manager TitleAgeSince
Chief Executive Officer 56 28/03/2023
Director of Finance/CFO 57 29/01/2024
Chief Tech/Sci/R&D Officer 50 08/04/2024
Director TitleAgeSince
Chairman 55 12/06/2024
Director/Board Member 56 24/05/2023
Director/Board Member 68 06/04/2023
Date Insider Type Main position Quantity % Market Cap.
05-20Free

Director

67,000 0.1200%
05-20
Baker Bros. Advisors LP
FreeCompany 134,000 0.2400%
05-20Free

Director

67,000 0.1200%
Change 5-day change 1-year change 3-year change Capi.($)
-0.74%-26.74%-47.85%-56.25% 60.33M
+3.13%+13.95%+64.21%+94.35% 57.82B
-0.40%-6.17%+53.83%+70.84% 53.71B
-0.27%-5.77%+6.75%+433.06% 23.8B
+1.76%-1.65%-16.86%-15.01% 23.26B
-0.56%+6.10%+44.56%-3.75% 20.7B
-0.75%-2.38%+33.95%-29.86% 17.81B
+10.00%-4.30%+208.33%+370.99% 16.9B
-2.61%+10.00%+47.02%+699.54% 16.36B
-0.39%-1.00%+26.08%+186.49% 13.96B
Average +0.92%-1.40%+42.00%+175.04% 24.44B
Weighted average by Cap. +1.19%+1.34%+51.35%+159.27%

Financials

2026 *2027 *
Net sales 7.56M 6.61M 6.1M 5.6M 10.62M 727M 10.8M 72.77M 28.55M 355M 28.38M 27.76M 1.23B 7.81M 6.83M 6.3M 5.79M 10.97M 751M 11.15M 75.17M 29.5M 367M 29.32M 28.68M 1.27B
Net income -115M -101M -92.81M -85.31M -162M -11.07B -164M -1.11B -435M -5.41B -432M -423M -18.65B -125M -109M -101M -92.54M -175M -12.01B -178M -1.2B -472M -5.87B -469M -458M -20.23B
Net Debt -98.87M -86.44M -79.74M -73.3M -139M -9.51B -141M -952M -374M -4.65B -371M -363M -16.03B -74.76M -65.36M -60.29M -55.42M -105M -7.19B -107M -720M -282M -3.52B -281M -275M -12.12B
Logo TScan Therapeutics, Inc.
TScan Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer. The Company's lead product candidate, TSC-101, is in development for the treatment of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) who are undergoing allogeneic hematopoietic cell transplantation (HCT). The Company is also developing multiple TCR-T therapy product candidates for the treatment of solid tumors. The Company builds a collection of therapeutic TCRs that recognize cancer-specific targets and are associated with multiple human leukocyte antigen (HLA) types, to provide customized multiplex TCR-T treatments for patients with a variety of solid tumors. Its solid tumors programs include TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204.
Employees
139
Date Price Change Volume
15/07/26 $0.9231 -0.74% 473,755
14/07/26 $0.9300 -9.71% 1,640,085
13/07/26 $1.030 -5.50% 1,152,419
10/07/26 $1.090 +2.83% 968,754
09/07/26 $1.060 -15.87% 1,266,274
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
0.9231USD
Average target price
6.000USD
Spread / Average Target
+549.98%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. TCRX Stock